100th つないで、進む FRONTIERS IN LIFE SCIENCE

検索の使い方

Breast Cancer Tissue Array For Antibody Screening , Including TNM And Pathology Grade, 50 Cases/100 Cores|ヒト組織アレイ

掲載日情報：2015/08/07 現在Webページ番号：172847

ティッシューアレイドットコム /
TissueArray.Com LLC
[メーカー略称：USB]

US Biomax社は、豊富なラインナップの組織アレイ、組織切片(凍結、FFPE)を提供しているメーカーです。
US Biomax社のヒト組織アレイ(Breast Cancer Tissue Array For Antibody Screening , Including TNM And Pathology Grade, 50 Cases/100 Cores)をご紹介します。

※ヒト組織アレイは、ドナーからインフォームドコンセントを取得した組織を使用しています。
※ドナーの組織は、HIV、Hepatitis B、Hepatitis Cが陰性であることを確認しています。
※本製品は研究用です。研究用以外には使用できません。

カートに商品を
追加しました。

ヒト組織アレイの価格

[在庫・価格 ：2024年06月05日 20時55分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
 納期 文献数
Breast cancer tissue array for antibody screening , including TNM and pathology grade
  • お問い合わせ
 2～3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 0
  • お問い合わせ
説明文
法規制等
保存条件 4℃ 法規備考
掲載カタログ

製品記事 TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド
関連記事 TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして

[在庫・価格 ：2024年06月05日 20時55分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Breast cancer tissue array for antibody screening , including TNM and pathology grade

文献数： 0

  • お問い合わせ

説明文
法規制等
保存条件 4℃ 法規備考
掲載カタログ

製品記事 TissueArray.Com社 組織アレイ(Tissue array) 選択ガイド
関連記事 TissueArray.Com社 パラフィン組織スライド／組織アレイの仕様変更につきまして
  • お問い合わせ

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイの特長

Microarray Panel: Breast carcinoma tissue microarray for antibody screening, containing 40 cases of breast invasive ductal carcinoma, 10 normal tissue, duplicate cores per case, divided into two identical 50 cores arrays
Cores: 100
組織アレイ
Cases: 50
Layout: 10 cols × 10 rows
Core Diameter: 1 mm
Thickness: 5 µm
Quality Control: Anti-Actin confirmed
Applications:

Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes: Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H and E: Hematoxylin and Eosin stained tissue array slide.

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイの仕様表

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM Type †
A1 1 F 39 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
A2 2 F 51 Breast Invasive ductal carcinoma (sparse) 2 IIa T2N0M0 Malignant
A3 3 F 48 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
A4 4 F 43 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
A5 5 F 47 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
A6 6 F 39 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
A7 7 F 51 Breast Invasive ductal carcinoma (breast tissue) – IIa T2N0M0 Malignant
A8 8 F 48 Breast Invasive ductal carcinoma with necrosis 2 IIa T2N0M0 Malignant
A9 9 F 43 Breast Invasive ductal carcinoma (chronic inflammation of breast tissue) – IIa T2N0M0 Malignant
A10 10 F 47 Breast Invasive ductal carcinoma (necrotic tissue) – IIa T2N0M0 Malignant
B1 11 F 49 Breast Invasive ductal carcinoma 2 IIb T3N0M0 Malignant
B2 12 F 49 Breast Invasive ductal carcinoma (sparse) 2 IIa T1N1M0 Malignant
B3 13 F 37 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
B4 14 F 62 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 Malignant
B5 15 F 27 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
B6 16 F 49 Breast Invasive ductal carcinoma 2 IIb T3N0M0 Malignant
B7 17 F 49 Breast Invasive ductal carcinoma 2 IIa T1N1M0 Malignant
B8 18 F 37 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
B9 19 F 62 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 Malignant
B10 20 F 27 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
C1 21 F 57 Breast Invasive ductal carcinoma (sparse) – IIb T2N1M0 Malignant
C2 22 F 61 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
C3 23 F 56 Breast Invasive ductal carcinoma 2 I T1N0M0 Malignant
C4 24 F 40 Breast Invasive ductal carcinoma 2 IIb T2N1M0 Malignant
C5 25 F 30 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 Malignant
C6 26 F 57 Breast Invasive ductal carcinoma (fibrofatty tissue) – IIb T2N1M0 Malignant
C7 27 F 61 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
C8 28 F 56 Breast Invasive ductal carcinoma 2 I T1N0M0 Malignant
C9 29 F 40 Breast Invasive ductal carcinoma 2 IIb T2N1M0 Malignant
C10 30 F 30 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 Malignant
D1 31 F 56 Breast Invasive ductal carcinoma (fibrofatty tissue) – IIIb T4N1M0 Malignant
D2 32 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
D3 33 F 60 Breast Invasive ductal carcinoma 3 I T1N0M0 Malignant
D4 34 F 59 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
D5 35 F 40 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 Malignant
D6 36 F 56 Breast Invasive ductal carcinoma (chronic inflammation of breast tissue) – IIIb T4N1M0 Malignant
D7 37 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
D8 38 F 60 Breast Invasive ductal carcinoma 3 I T1N0M0 Malignant
D9 39 F 59 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
D10 40 F 40 Breast Invasive ductal carcinoma 2 IIIb T4N0M0 Malignant
E1 41 F 38 Breast Invasive ductal carcinoma 2 I T1N0M0 Malignant
E2 42 F 50 Breast Invasive ductal carcinoma 2 IIb T3N0M0 Malignant
E3 43 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
E4 44 F 58 Breast Invasive ductal carcinoma 2 IIIb T4N1M0 Malignant
E5 45 F 56 Breast Invasive ductal carcinoma 2 IIb T3N0M0 Malignant
E6 46 F 38 Breast Invasive ductal carcinoma 2 I T1N0M0 Malignant
E7 47 F 50 Breast Invasive ductal carcinoma 2 IIb T3N0M0 Malignant
E8 48 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
E9 49 F 58 Breast Invasive ductal carcinoma 2 IIIb T4N1M0 Malignant
E10 50 F 56 Breast Invasive ductal carcinoma (sparse) 2 IIb T3N0M0 Malignant
F1 51 F 62 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
F2 52 F 64 Breast Invasive ductal carcinoma 2 IIb T3N1M0 Malignant
F3 53 F 47 Breast Invasive ductal carcinoma (sparse) 2 IIa T2N0M0 Malignant
F4 54 F 54 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
F5 55 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
F6 56 F 62 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
F7 57 F 64 Breast Invasive ductal carcinoma 2 IIb T3N1M0 Malignant
F8 58 F 47 Breast Invasive ductal carcinoma (sparse) – IIa T2N0M0 Malignant
F9 59 F 54 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
F10 60 F 50 Breast Invasive ductal carcinoma 2 IIa T2N0M0 Malignant
G1 61 F 48 Breast Invasive ductal carcinoma (sparse) – IIa T2N0M0 Malignant
G2 62 F 35 Breast Invasive ductal carcinoma 3 I T1N0M0 Malignant
G3 63 F 52 Breast Invasive ductal carcinoma 3 IIIb T4N0M0 Malignant
G4 64 F 37 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
G5 65 F 52 Breast Invasive ductal carcinoma 3 IIb T2N1M0 Malignant
G6 66 F 48 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
G7 67 F 35 Breast Invasive ductal carcinoma 3 I T1N0M0 Malignant
G8 68 F 52 Breast Invasive ductal carcinoma 3 IIIb T4N0M0 Malignant
G9 69 F 37 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
G10 70 F 52 Breast Invasive ductal carcinoma 3 IIb T2N1M0 Malignant
H1 71 F 70 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H2 72 F 47 Breast Invasive ductal carcinoma 3 I T1N0M0 Malignant
H3 73 F 74 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H4 74 F 52 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H5 75 F 66 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H6 76 F 70 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H7 77 F 47 Breast Invasive ductal carcinoma 3 I T1N0M0 Malignant
H8 78 F 74 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H9 79 F 52 Breast Invasive ductal carcinoma 3 IIa T2N0M0 Malignant
H10 80 F 66 Breast Invasive ductal carcinoma (sparse) 3 IIa T2N0M0 Malignant
I1 81 F 48 Breast Cancer adjacent normal breast tissue – – – NAT
I2 82 F 51 Breast Cancer adjacent normal breast tissue – – – NAT
I3 83 F 43 Breast Cancer adjacent normal breast tissue – – – NAT
I4 84 F 35 Breast Cancer adjacent normal breast tissue – – – NAT
I5 85 F 46 Breast Cancer adjacent normal breast tissue – – – NAT
I6 86 F 48 Breast Cancer adjacent normal breast tissue – – – NAT
I7 87 F 51 Breast Cancer adjacent normal breast tissue (fibrofatty tissue) – – – NAT
I8 88 F 43 Breast Cancer adjacent normal breast tissue – – – NAT
I9 89 F 35 Breast Cancer adjacent normal breast tissue (fibrofatty tissue) – – – NAT
I10 90 F 46 Breast Cancer adjacent normal breast tissue (fibrofatty tissue) – – – NAT
J1 91 F 46 Breast Cancer adjacent normal breast tissue – – – NAT
J2 92 F 35 Breast Cancer adjacent normal breast tissue – – – NAT
J3 93 F 35 Breast Normal breast tissue – – – Normal
J4 94 F 27 Breast Normal breast tissue – – – Normal
J5 95 F 50 Breast Normal breast tissue – – – Normal
J6 96 F 46 Breast Cancer adjacent normal breast tissue – – – NAT
J7 97 F 35 Breast Cancer adjacent normal breast tissue – – – NAT
J8 98 F 35 Breast Normal breast tissue (fibrofatty tissue) – – – Normal
J9 99 F 27 Breast Normal breast tissue – – – Normal
J10 100 F 50 Breast Normal breast tissue – – – Normal
– – M 58 Skin Malignant melanoma (tissue marker) – Malignant

*For precise diagnosis, refer to pathology description.

目次に戻る

カートに商品を
追加しました。

ヒト組織アレイのFAQ

US BIOMAX社ヒト組織アレイのFAQはこちら。

目次に戻る

カートに商品を
追加しました。

お問い合わせ先

（テクニカルサポート 試薬担当）

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。